SCYNEXIS, Inc. is a pharmaceutical company. It is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. It also provides contract research and development services. SCYNEXIS, Inc. is headquartered in Durham, North Carolina.
Revenue (Most Recent Fiscal Year) | $3.75M |
Net Income (Most Recent Fiscal Year) | $-21.29M |
PE Ratio (Current Year Earnings Estimate) | -- |
PE Ratio (Trailing 12 Months) | -- |
PEG Ratio (Long Term Growth Estimate) | -- |
Price to Sales Ratio (Trailing 12 Months) | 10.75 |
Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.73 |
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
Pre-Tax Margin (Trailing 12 Months) | -610.71% |
Net Margin (Trailing 12 Months) | -599.05% |
Return on Equity (Trailing 12 Months) | -43.04% |
Return on Assets (Trailing 12 Months) | -28.21% |
Current Ratio (Most Recent Fiscal Quarter) | 5.20 |
Quick Ratio (Most Recent Fiscal Quarter) | 5.20 |
Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
Inventory Turnover (Trailing 12 Months) | -- |
Book Value per Share (Most Recent Fiscal Quarter) | $1.06 |
Earnings per Share (Most Recent Fiscal Quarter) | $-0.14 |
Earnings per Share (Most Recent Fiscal Year) | $-0.60 |
Diluted Earnings per Share (Trailing 12 Months) | $-0.40 |
Exchange | NASDAQ |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Common Shares Outstanding | 41.92M |
Free Float | 39.89M |
Market Capitalization | $35.01M |
Average Volume (Last 20 Days) | 0.19M |
Beta (Past 60 Months) | 1.64 |
Percentage Held By Insiders (Latest Annual Proxy Report) | 4.86% |
Percentage Held By Institutions (Latest 13F Reports) | 54.37% |
Annual Dividend (Based on Last Quarter) | $0.00 |
Dividend Yield (Based on Last Quarter) | 0.00% |